These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 15522998)

  • 1. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice.
    Kawasaki F; Matsuda M; Kanda Y; Inoue H; Kaku K
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E510-8. PubMed ID: 15522998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes.
    Diani AR; Sawada G; Wyse B; Murray FT; Khan M
    Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E116-22. PubMed ID: 14532171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.
    Ishida H; Takizawa M; Ozawa S; Nakamichi Y; Yamaguchi S; Katsuta H; Tanaka T; Maruyama M; Katahira H; Yoshimoto K; Itagaki E; Nagamatsu S
    Metabolism; 2004 Apr; 53(4):488-94. PubMed ID: 15045697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].
    Song LL; Xiao JZ; Yang WY; Zhang M; Liu BB; Pan L
    Zhonghua Nei Ke Za Zhi; 2011 Sep; 50(9):781-4. PubMed ID: 22176969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
    Yajima K; Hirose H; Fujita H; Seto Y; Fujita H; Ukeda K; Miyashita K; Kawai T; Yamamoto Y; Ogawa T; Yamada T; Saruta T
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E966-71. PubMed ID: 12676649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
    Kawashima S; Matsuoka TA; Kaneto H; Tochino Y; Kato K; Yamamoto K; Yamamoto T; Matsuhisa M; Shimomura I
    Biochem Biophys Res Commun; 2011 Jan; 404(1):534-40. PubMed ID: 21144823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
    Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
    Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.
    Kanda Y; Shimoda M; Hamamoto S; Tawaramoto K; Kawasaki F; Hashiramoto M; Nakashima K; Matsuki M; Kaku K
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E278-86. PubMed ID: 19920213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
    Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
    Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elovl6 Deficiency Improves Glycemic Control in Diabetic
    Zhao H; Matsuzaka T; Nakano Y; Motomura K; Tang N; Yokoo T; Okajima Y; Han SI; Takeuchi Y; Aita Y; Iwasaki H; Yatoh S; Suzuki H; Sekiya M; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
    Diabetes; 2017 Jul; 66(7):1833-1846. PubMed ID: 28461456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice.
    Diani AR; Peterson T; Sawada GA; Wyse BM; Gilchrist BJ; Hearron AE; Chang AY
    Diabetologia; 1984 Aug; 27(2):225-34. PubMed ID: 6386585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
    Matsui J; Terauchi Y; Kubota N; Takamoto I; Eto K; Yamashita T; Komeda K; Yamauchi T; Kamon J; Kita S; Noda M; Kadowaki T
    Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochemical analysis of pancreatic islet hypercytolipidemia following diabetes (db/db) and obese (ob/ob) mutation expression: influence of genomic background.
    Garris DR; Garris BL
    Pathobiology; 2004; 71(5):231-40. PubMed ID: 15459481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
    Fujiwara T; Wada M; Fukuda K; Fukami M; Yoshioka S; Yoshioka T; Horikoshi H
    Metabolism; 1991 Nov; 40(11):1213-8. PubMed ID: 1943750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogenic restoration of functional pancreatic islet cytoarchitecture in diabetes (db/db) mutant C57BL/KsJ mice: relationship to estradiol localization, systemic glycemia, and persistent hyperinsulinemia.
    Garris DR; Garris BL
    Cell Tissue Res; 2005 Feb; 319(2):231-42. PubMed ID: 15654653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
    de Souza CJ; Yu JH; Robinson DD; Ulrich RG; Meglasson MD
    Diabetes; 1995 Aug; 44(8):984-91. PubMed ID: 7622005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.